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Autosomal-dominant hypophosphatemic rickets (ADHR) mu- genes causing rare, heritable disorders of impaired phos-
tations stabilize FGF-23. phate regulation provides an opportunity to discover novel
Background. The gene for the renal phosphate wasting dis- renal pathways that control mineral ion balance. Auto-order autosomal-dominant hypophosphatemic rickets (ADHR)
somal-dominant hypophosphatemic rickets (ADHR, MIMis FGF23, which encodes a secreted protein related to the fi-
broblast growth factors (FGFs). We previously detected mis- no. 193100) is a phosphate wasting disorder that maps to
sense mutations R176Q, R179W, and R179Q in FGF23 from chromosome 12p13 and is characterized by short stature,
ADHR kindreds. The mutations replace R residues within a sub- bone pain, fracture and lower extremity deformity [1, 2].tilisin-like proprotein convertase (SPC) cleavage site 176RHTR-
We recently identified the gene causing ADHR as FGF23,179 (RXXR motif). The goal of these studies was to determine
if the ADHR mutations lead to protease resistance of FGF-23. which encodes a novel, secreted protein [3] that shares
Methods. The ADHR mutations were introduced into hu- 25 to 35% homology with the fibroblast growth factor
man FGF-23 cDNA clones with or without an N-terminal FLAG (FGF) family [4]. Previous studies demonstrated thattag by site-directed mutagenesis and were transiently trans-
FGF-23 is overexpressed in tumors that lead to onco-fected into HEK293 cells. Protein expression was determined
by Western analyses. genic hypophosphatemic osteomalacia (OHO) [3, 5], an
Results. Antibodies directed toward the C-terminal portion acquired disorder of renal phosphate wasting. Patients
of FGF-23 revealed that the native FGF-23 protein resolved
with OHO share biochemical and clinical similarities withas 32 kD and 12 kD species in HEK293 conditioned media;
ADHR patients including hypophosphatemia, decreasedhowever, the three mutated proteins were detected only as
the 32 kD band. An N-terminal FLAG-tagged native FGF-23 or inappropriately normal serum 1,25(OH)2 vitamin D3
resolved as two bands of 36 kD and 26 kD when detected concentrations, osteomalacia, and reduced tubular maxi-
with a FLAG antibody, whereas the R176Q mutant resolved
mum reabsorption of phosphate (TMP)/glomerular fil-primarily as the 36 kD protein species. Cleavage of FGF-23
tration rate (GFR) [1, 6, 7]. As OHO is completely re-was not enhanced by extracellular incubation of FGF-23 with
HEK293 cells. Native and mutant FGF-23s bound heparin. solved upon surgical removal of the tumor, it has been
Conclusions. FGF-23 proteins containing the ADHR muta- proposed that a phosphaturic substance secreted by the
tions are secreted, and produce polypeptides less sensitive to
tumor may give rise to the renal phosphate wasting [8, 9].protease cleavage than wild-type FGF-23. Therefore, the ADHR
Most secreted and membrane-bound proteins undergomutations may protect FGF-23 from proteolysis, thereby poten-
tially elevating circulating concentrations of FGF-23 and lead- post-translational modification before expression of the
ing to phosphate wasting in ADHR patients. mature polypeptide. The subtilisin-like proprotein con-
vertases (SPCs) are a seven member family of serine
proteases involved in the processing of neuropeptides,The kidney plays a major role in maintaining proper
peptide hormones, growth factors, membrane-bound re-serum phosphate concentrations through mechanisms
ceptors, blood coagulation factors, and plasma proteinsthat are not completely understood. The identification of
[reviewed in 10–12]. The SPC substrates are cleaved
C-terminal to the basic motif K/R-Xn-K/R, where Xn 
Key words: FGF23, 12p13, chromosome 12, hypophosphatemia, site-
2, 4, or 6 residues of any amino acid, although rarelydirected mutagenesis, proprotein convertase, renal phosphate wasting,
fibroblast growth factor. Cys [10, 11]. These enzymes are largely expressed in the
trans-Golgi-network, and possess similar, but not exactReceived for publication April 27, 2001
substrate specificities [10–12]. In our previous geneticand in revised form July 19, 2001
Accepted for publication July 23, 2001 study, four ADHR kindreds were shown to have FGF23
missense mutations in one of two R residues that are 2001 by the International Society of Nephrology
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Table 1. Primers for FGF-23 mutagenesis cDNAs was amplified with the 5FGF23 and 3FGF23
primers. The resulting products were then digested withPrimer
Mutant orientation Sequence (5–3) BamHI and EcoRI and directionally ligated into the
5FGF23 Primer Forward CGGGATCCACGATGTTGGGGGCCCG expression plasmid pcDNA3.1() (InVitrogen; Carls-
3FGF23 Primer Reverse GGAATTCCTAGATGAACTTGGCGAA bad, CA, USA) to create the mutant clones pR176Q,
R176Q (G527A) Forward ATACCACGGCAGCACACCCGG
pR179W, and pR179Q. Each mutant clone insert was se-R176Q (G527A) Reverse CCGGGTGTGCTGCCGTGGTAT
R179W (C535T) Forward GCGGCACACCTGGAGCGCCGA quenced to confirm that the appropriate mutations were
R179W (C535T) Reverse TCGGCGCTCCAGGTGTGCCGC introduced, as well as to assure the integrity of the ORF.
R179Q (G536A) Forward CGGCACACCCAGAGCGCCGAG
R179W (G536A) Reverse CTCGGCGCTCTGGGTGTGCCG
N-terminal FLAG constructs
The BamHI and EcoRI sites located within in the 5FGF23 and 3FGF23
primers, respectively, are italicized and double underlined. The mutated base To create N-terminal FLAG (residues DYKDDDDK)
within each primer is underlined. tagged fusion constructs for native and R176Q mutant
FGF23, pFGF23 and pR176Q were amplified separately
with the primers: forward (contains the EcoRI site, under-
lined) 5GGAATTCATATCCCAATGCCTCCCCA3separated by only two amino acids: R176Q (G527A),
and reverse (contains the BamHI site, underlined) 5CGR179W (C535T), and R179Q (G536A) [4]. The FGF-23
GGATCCCTAGATGAACTTGGCGAA3. The result-mutations lead to replacement of either of two critical
ing cDNAs were digested with EcoRI and BamHI, andR residues within a potential SPC minimum consensus
directionally ligated into the pFLAG-CMV-3 expressioncleavage site: 176RHTR179 (RXXR motif).
vector (Sigma-Aldrich, Inc. St. Louis, MO, USA), whichThe molecular and physiological mechanisms by which
uses the preprotrypsin leader sequence to allow secretionthe naturally occurring mutations in FGF-23 lead to mis-
of N-terminal FLAG tagged fusion proteins. The cloneregulation of renal phosphate handling and ADHR are
inserts were sequenced to confirm the proper readingcurrently unknown. Therefore, the goal of these studies
frame of the fusion protein.was to test whether the ADHR missense mutations are
expressed and secreted in a manner similar to native Plasmid purification and DNA sequencing
FGF-23, as well as to determine if the ADHR mutations
Plasmids were isolated with the Qiagen Mini- and Maxi-
stabilize secreted FGF-23, possibly through the disrup-
Prep Kits (QIAgen, Inc., Valencia, CA, USA) according
tion of a predicted SPC cleavage motif. to the manufacturer’s instructions and subjected to se-
quencing using the Thermosequenase Kit (Amersham,
Inc.; Cleveland, OH, USA) with [-33P] ddNTP (Amer-METHODS
sham) incorporation. Sequenced products were sepa-Site-directed mutagenesis of human pFGF23
rated on a standard 0.2 mm, 6% polyacrylamide gel and
The three ADHR FGF-23 missense mutations were autoradiography was performed.
introduced into the FGF-23 cDNA using a nested poly-
merase chain reaction (PCR), site-directed mutagenesis Cell culture
approach [13]. The high-fidelity DNA polymerase Pfu HEK293 cells (ATCC, Manassas, VA, USA) were
(Promega, Inc.; Madison, WI, USA) was used in all PCR cultured in Dulbecco’s modified Eagle’s medium-F12
reactions and the pFGF23 expression plasmid containing (DMEM-F12; Gibco BRL; Rockville, MD, USA) with
the native FGF-23 cDNA (bp 3 to 756) cloned into 10% fetal bovine serum (FBS; Hyclone; Logan, UT,
pcDNA3.1() [3] served as the template. For the initial USA) at 37C and 5% CO2.
round of PCR each forward mutagenic primer, containing
Transient transfectionthe appropriate missense mutation (primer sequences,
Table 1), was paired with the reverse 3FGF23 primer HEK293 cells (5 106) were seeded on 100 mm culture
and each reverse mutagenic primer was paired with the dishes (Fisher, Inc.; Pittsburgh, PA, USA) and tran-
forward 5FGF23 primer. PCR conditions for all experi- siently transfected in serum-free media with the Fugene
ments were: one minute at 95C, followed by 35 cycles 6 reagent (Hoffmann-La Roche, Inc.; Nutley, NJ, USA)
of one minute at 95C, one minute at 55C, two minutes using 10 g of plasmid DNA according to the manufac-
at 72C, and a final extension of seven minutes at 72C. turer’s instructions. Transfection efficiency was assessed
The resulting cDNA products from the first round of by co-transfection of a 	-galactosidase reporter plasmid
PCR were gel purified using the Wizard Prep Kit (Pro- and X-gal staining by standard protocols [14]. After
mega, Inc.). The second round of PCR was used to pro- transfection, the incubation was continued for an addi-
duce full-length mutant cDNAs; 1 L from each of the tional 48 hours. Conditioned media were concentrated
two initial PCR reactions for a specific mutant was com- 25 to 50 times with Centricon-10 columns (Millipore,
Inc., Bedford, MA, USA) at 4C.bined into a single reaction tube and this mixture of two
White et al: Mutant FGF-23 protein analysis 2081
FGF-23 heparin binding from the pFGF23-transfected cells (Fig. 1), consistent
with earlier results [3]. In contrast, only the 32 kD bandHEK293 cell media conditioned with native or mutant
was detected in the conditioned media from the mutantsFGF-23s, or vector control media (0.5 mL), were added
(Fig. 1), and there was no apparent difference in the1:1 with 1  phosphate buffered saline (PBS), pH 7.4,
level of expression between the native and the FGF-23as well as 50 L of a 1:1 heparin sepharose:1  PBS
mutants. In addition, total cellular lysates were negative(Amersham Pharmacia, Inc.; Piscataway, NJ, USA) sus-
(Fig. 1), as were vector-control transfections [3]. There-
pension. The mixture was placed on a rotating platform
fore, transiently transfected mammalian cell lines can
at 4C for four hours to bind FGF-23 to the heparin, secrete the FGF-23 mutants; however, only the larger
then centrifuged for one minute to collect the FGF-23- protein species could be detected with our polyclonal
heparin-sepharose complex. The supernatant was re- antibody.
moved, and the sepharose was washed four times with The FGF-23 antibody epitope is C-terminal to the
ice-cold 1  PBS. Laemmli sample buffer (50 L) was potential SPC cleavage site at residues 176–179. Thus,
added to the sepharose and the suspension was briefly the 12 kD bands from the native FGF-23 protein could
vortexed, and then boiled for five minutes to denature be the C-terminal fragments of the 32 kD species. If the
and separate the bound FGF-23 from the heparin. The 12 kD species detected above is a breakdown product,
samples were centrifuged for one minute and the super- an antibody upstream to the SPC cleavage site should
natants containing the previously bound protein were bind the larger protein species as well as the N-terminal
removed. Ten microliters of each supernatant was elec- protein fragment. Therefore, to determine if the ADHR
mutations inhibited the cleavage of FGF-23, and to deter-trophoresed on a 15% acrylamide gel and transferred to
mine if we could detect N-terminal fragments of FGF-23,nitrocellulose for Western blot analysis.
an N-terminal FLAG epitope-tagged native FGF-23,
FLAG-R176Q mutant, and vector control were tran-Western analysis
siently transfected into HEK293 cells. The conditionedProtein concentrations were determined by Bradford
media were analyzed by Western blotting with an anti-protein assay (Bio-Rad, Inc., Hercules, CA, USA) with
FLAG monoclonal antibody. Two bands of 36 and 26 kDbovine serum albumin (BSA) as the standard. Protein
were detected with N-terminal FLAG-tagged nativesamples and standards, for molecular mass determina-
FGF-23 (Fig. 2). The R176Q mutant resolved primarilytion, were electrophoresed on 15% sodium dodecyl-poly-
as the 36 kD protein species, with a very minor band
acrylamide gel electrophoresis (SDS-PAGE) mini-gels detectable at 26 kD (Fig. 2). The vector control media
(Bio-Rad, Inc.) and electroblotted onto nitrocellulose produced no reactive bands, nor did the cellular lysates
membranes (Bio-Rad). Membranes were incubated with (not shown). The larger FLAG-pFGF23 protein species
2.5 g/mL anti-human FGF-23 polyclonal or anti-FLAG detected in the media migrates at 36 kD, as opposed to
M2 monoclonal (Sigma-Aldrich, Inc.) antibodies. The 32 kD observed in Figure 1 because of the additional
polyclonal antibody is an affinity purified IgG to FGF-23 residues from the FLAG tag. This was confirmed by using
residues 206-222 that recognizes recombinant human the polyclonal FGF-23 antibody for Western analyses of
FGF-23 protein by Western analysis [3]. Blots were incu- the same media, which also recognized the 36 kD species
bated with goat anti-rabbit-HRP or anti-mouse-HRP (not shown). These results indicate that the smaller
secondary antibodies (1:3000; Bio-Rad), and visualized bands detected in Western blots from the native FGF-23
are indeed C- and N-terminal fragments of FGF-23, andby enhanced chemiluminescence (ECL; Amersham, Inc.).
that the mutant FGF-23 proteins are secreted primarily
as the larger protein species. Therefore, replacing either
RESULTS critical R residue with the naturally occurring ADHR
mutations at position 176 or 179 stabilizes the 32 kDMutant FGF-23 expression by mammalian cells
FGF-23 protein.
To test whether the human FGF-23 isoforms contain-
ing the ADHR missense mutations could be secreted by Intracellular versus extracellular cleavage of
mammalian cells, HEK293 cells were transiently trans- native FGF23
fected with native pFGF23, or the pR176Q, pR179W, To determine whether the cleavage of FGF-23 by
pR179Q plasmids. Western blot analysis was then per- HEK293 cells observed in vitro was an intra- or extracel-
formed on conditioned media and on total cellular ly- lular process, FGF-23 conditioned medium was incu-
sates derived from the transfected cells, using a charac- bated with control HEK293 cells not expressing pFGF23,
terized antibody that recognizes human FGF-23 [3]. or placed directly into an empty tissue culture dish for
Immunoreactive proteins of approximately 32 kD and a 24 hours at 37C and 5% CO2. After incubation, the
media was collected, concentrated to the same volume,doublet at 12 kD were detected in the conditioned media
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Fig. 1. Analysis of native and mutant FGF-23
proteins. Western analysis was performed with
a polyclonal antibody to human FGF-23 using
2 g conditioned media and 50 g cellular
lysates from HEK293 cells transfected with
pFGF23, pR176Q p179W, and p179Q. Bands
of 32 and 12 kD were detected for native
FGF-23, whereas only the 32 kD species was
detected for the mutants. Cellular lysates were
negative, and all constructs showed similar
transfection efficiencies. Protein size stan-
dards are shown to the right of the native
FGF23 blots for orientation.
Fig. 2. N-terminal FLAG epitope tagged FGF-
23 expression. Western analysis was used to de-
tect FLAG epitope tagged native (two individ-
ual clones, left two lanes) or R176Q mutant
FGF-23 (two individual clones, right two lanes)
with the M2 FLAG monoclonal antibody in
conditioned media from transiently transfected
HEK293 cells. Native FLAG-FGF23 was de-
tected as a 36 kD band and a pronounced
26 kD fragment, whereas the FLAG-R176Q
mutant resolved primarily as the 36 kD spe-
cies, with a faint band resolving at 26 kD. Pro-
tein size standards are shown on the far right.
A schematic of FGF-23 protein showing the
relative positions of the FLAG and FGF-23
antibody epitopes, as well as the SPC cleavage
site is shown below the Western analysis.
and subjected to Western analysis using the C-terminal mutations interfered with FGF-23 heparin binding. Con-
ditioned media containing FGF-23 and the three mutantsanti-FGF23 antibody. There was no change in the ratio
of the 32 kD band to the 12 kD band regardless of the were incubated separately with conjugated heparin-sepha-
rose, and then the material that bound was subjected totreatment of the conditioned media (Fig. 3), indicating
that the cleavage of FGF-23 occurred intracellularly, ei- Western analysis. The 32 kD protein species of the native
and the FGF-23 mutants was detected, whereas the vectorther before or during cellular secretion, and not by extra-
cellular proteases expressed on HEK293 cells. control media was negative (Fig. 4). FGF-23 conditioned
media incubated with unconjugated sepharose was also
Heparin binding of FGF-23 negative (not shown), indicating that the binding was
dependent upon heparin. In addition, the FLAG-taggedThe FGF-23 mutations in R176 and R179 are adjacent
to 	 strands that contain potential FGF heparin binding native and FLAG-R176Q proteins bound heparin, and
migrated as before at 36 kD (Fig. 4). These results dem-motifs [4], and therefore, we tested whether the ADHR
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Fig. 4. Determination of heparin binding by native and mutant FGF-23s.
Conditioned media from HEK293 cells containing native or mutant
FGF-23 protein, and N-terminal FLAG epitope tagged native FGF-23
or R176Q, were incubated with heparin-sepharose and the bound mate-
rial subjected to Western blot analysis with the FGF-23 polyclonal
antibody. The 32 kD species for native and mutant FGF-23s, as well
as the 36 kD species of FLAG-FGF-23 and FLAG-R176Q bound hepa-
rin. The media for the respective vector controls were negative. TheFig. 3. Analysis of extracellular exposure of FGF-23 to HEK293 cells.
origin of the faint band in some samples at approximately 28 kD isLeft two lanes, Western analysis was performed with the FGF-23 poly-
currently unknown. Molecular mass size standards are shown far right.clonal antibody on FGF-23 conditioned medium that was incubated for
24 hours with HEK293 cells (5  106) or in an empty culture dish.
There was no difference in the intensity of the 32 kD and 12 kD bands
after the treatments. Right two lanes, Coomassie blue staining of the
samples electrophoresed in parallel confirmed equal gel loading. Protein from the mutant-transfected cells, and the FLAG-taggedstandards are shown to the right of the stained gel for orientation.
N-terminal proteolytic fragments were detected as an
extremely minor form of the mutants (Fig. 2). The fact
that we could detect the mutant N-terminal fragments,
but could not detect the C-terminal fragments, mostonstrate that the 32 kD species of FGF-23 specifically
likely reflects that the FLAG monoclonal antibody hasbinds heparin, and provides biochemical evidence that
a higher affinity for its epitope than does the polyclonalFGF-23 is indeed a member of the heparin-binding FGF
FGF-23 antibody for its respective epitope. The observa-family. In addition, gross loss of FGF-23 structure due
tion that the full-length FGF-23 polypeptide appears moreto the missense mutations most likely does not occur
intense upon Western analysis when using a C-terminalsince the mutants retain heparin binding.
antibody than when using an N-terminal antibody may
indicate that FGF-23 undergoes post-translational modi-
DISCUSSION fication near the N-terminus, and therefore access of
The processing of prepro- and pro-polypeptides to a the M2 antibody to the FLAG epitope may be partially
mature form is critical for proper secretion or intracellu- restricted for the full-length protein. Since the mutants
lar localization. Many of the secreted factors that influ- are not cleaved as efficiently as wild-type FGF-23, and
ence renal and bone mineral homeostasis, such as the bone are associated with phosphate wasting in ADHR patients
morphogenic proteins (BMPs) [15], transforming growth [4], stabilization and secretion of the full-length protein,
factors (TGFs) [16], parathyroid hormone (PTH) [17], as opposed to secretion of the proteolytic fragments, may
and PTH-related peptide (PTHrP) [18] undergo cleavage lead to renal phosphate wasting. At this time, however,
by the SPC family to activate the molecules. We dem- because the SPC family is often associated with activation
onstrated that native FGF-23 protein is sensitive to pro- of their substrates, we cannot rule out a possible biologi-
tease cleavage, whereas the naturally occurring R176Q-, cal role for the native FGF-23 cleavage products under
R179W-, and R179Q-FGF-23 mutants are largely resis- normal physiological conditions, perhaps as autocrine or
tant to cleavage after transient transfection in vitro (Figs. paracrine agents, as is the case with other members of
1 and 2). In support of this observation, analysis with the FGF family [19, 20]. Our results also indicate that
our polyclonal antibody to FGF-23 failed to detect the ADHR most likely does not arise from FGF-23 haplo-
insufficiency because we demonstrated that the mutantsC-terminal fragments of FGF-23 in conditioned media
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are efficiently translated and secreted by mammalian cells cause changes in secondary structure that lead to mispro-
cessing at other sites in the polypeptide either before or(Fig. 1). Furthermore, tumors from patients with onco-
genic hypophosphatemic osteomalacia (OHO), over- after secretion. The former possibility is the most likely
because R176-R179 comprise the only predicted prote-express FGF-23 mRNA and protein [3] and others have
shown that full-length FGF-23, as opposed to the frag- ase processing site, mutating either R residue inhibits
cleavage, and the three different ADHR residue substi-ments, when injected, results in hypophosphatemia in
vivo [abstract; Shimada, Bone 28(Suppl 5):S89, 2001]. tutions result in the same stability of FGF-23. Also, mem-
bers of the SPC family are thought to cycle between intra-These results support the idea that FGF-23 is a phospha-
turic substance and indicate that ADHR does not arise cellular compartments and the plasma membrane [25],
and hence circulating FGF-23 potentially could be cleavedfrom inactivating mutations in a phosphate conserving
factor, but rather that the mutations likely enhance the extracellularly by a plasma membrane-bound protease.
As the SPC enzymes share overlapping specificitiesbiological activity of FGF-23 in a phosphate wasting role.
Our previous studies demonstrated that FGF-23 is [26], it is difficult at this time to assess which of the family
members may be responsible for the cleavage of FGF-23.most likely expressed at low levels under normal circum-
stances. In situ hybridization of embryonic and adult Other members of the FGF family, such as FGF-3, are
processed by protease cleavage. Interestingly, Xenopusmouse tissues, as well as multiple tissue Northern blots
of human mRNAs failed to detect FGF-23 transcripts, and mouse FGF-3 homologs are proteolytically pro-
cessed at RQRR or RLRR motifs, respectively, from aand RT-PCR was required to detect FGF-23 in RNA
from human tissues [4]. Several of the SPCs also demon- 31 kD form to a 27 kD species with increased biological
activity [27]. Extracellular cleavage of FGF-3 by exoge-strate low cellular expression [21]. Therefore it is possible
that if FGF-23 is normally co-expressed with the SPC nous plasminogen was determined in vitro, and may indi-
cate that processing of FGF-23 after secretion also isenzymes at low levels, then the majority of native FGF-23
may be cleaved into fragments before or during secre- possible [27]. Evidence supporting the cleavage and acti-
vation of growth factors related to the FGFs that playtion. Speculatively, up-regulation of wild-type FGF-23
transcription and translation, in the case of a cytomegalo- important roles in bone growth and development by the
SPCs include platelet-derived growth factor (PDGF)-Avirus (CMV) promoter-driven construct (the present
study, Fig. 1) or in OHO [3], may overwhelm the SPCs, and -B [28], pro-TGF-	 [29], and insulin-like growth
factor (IGF)-I and -II [30, 31]. In addition, secreted fac-and the major portion of FGF-23 would be secreted as
full-length. In support of this idea, we detected only the tors have the potential to be processed by more than
one SPC family member, such as bone morphogenic32 kD FGF-23 protein species in a tumor causing OHO
[3] and did not detect R176 or R179 FGF-23 mutations protein-4 (BMP4), which shows enhanced cleavage in
the presence of furin or SPC6 [32]. Indeed, the cells thatin DNA from OHO tumors (unpublished observations).
In the case of ADHR, however, the mutations produce secrete FGF-23 in vivo may express different SPCs than
the model HEK293 system that we used for the presenta form of FGF-23 that is resistant to protease cleavage
(Figs. 1 and 2). Therefore, it is possible that the full- studies. Therefore, we cannot rule out other modifica-
tions to FGF-23 in its natural tissue. However, we havelength species may rise in patients’ bloodstreams until a
critical concentration is reached, and phosphate wasting previously expressed FGF-23 in cells from other species
including OK/E and COS-7 cells, both of which demon-occurs. At this time, however, we cannot rule out further
processing of native and mutant FGF-23 after secretion strated similar processing as HEK293 cells [3]. Future
studies should focus on determining the SPC enzymesby extracellular proteases, although no further break-
down of FGF-23 protein by HEK293 cell surface prote- involved in FGF-23 processing, and their potential roles
as therapeutic targets in regulating renal phosphate ho-ases was detected (Fig. 3). X-linked hypophosphatemia,
or XLH, arises from inactivating mutations in the PHEX meostasis.
It has been established that an important feature ofgene [22], which encodes a membrane-bound endopepti-
dase [23]. It has been proposed that PHEX may function FGF bioactivity involves the interaction between FGF,
the FGF receptors (FGFRs) and heparin [33]. The mem-to inactivate a phosphate-wasting factor [24]. Whether
FGF-23 is a substrate for, and is inactivated by PHEX, bers of the FGF family bind to one or several of four ty-
rosine kinase FGFRs (FGFR1–4), each of which hasis not clear at this time; however, a scenario could be
envisioned whereby the lack of PHEX expression in multiple splice variants [34]. Heparin is essential for
proper FGF binding to its cognate FGFR [33] and subse-XLH patients, or a mutation in the PHEX catalytic site,
results in an accumulation of native FGF-23, and then quent activation of the heteropentameric receptor com-
plex [33]. Solving the crystal structure of FGF1 com-to subsequent renal phosphate wasting. Cleavage of
FGF-23 is most likely inhibited directly at R179 due to plexed with FGFR2 and heparin indicated that heparin
decasaccharide forms a linkage between two FGF1 li-the ADHR mutations in the RXXR motif. However, we
cannot entirely rule out the possibility that the mutations gands that bridges between two receptor chains [35].
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tabolite levels in oncogenic osteomalacia. Ann Intern Med 93:279–The FGF-23 missense mutations in R176 and R179 are
280, 1980
adjacent to 	 strands 11 and 12 that, in tandem with 	 7. Tenenhouse HS, Econs MJ: Mendelian hypophosphatemias, in
The Metabolic and Molecular Basis of Inherited Disease, edited bystrands 1 and 2 in the FGF core region, contain the puta-
Scriver CR, New York, McGraw-Hill, 1998tive FGF-heparin binding domain [4]. Our studies demon-
8. Cai Q, Hodgson SF, Kao PC, et al: Brief report: Inhibition of
strate that native FGF-23 and the naturally occurring renal phosphate transport by a tumor product in a patient with
oncogenic osteomalacia. N Engl J Med 330:1645–1649, 1994ADHR mutants bind heparin (Fig. 4), thus supporting
9. Econs MJ, Drezner MK: Tumor-induced osteomalacia-unveilingthe idea that the mutations do not interrupt the heparin-
a new hormone. N Engl J Med 330:1679–1681, 1994
binding motif. Furthermore, because the FGF-23 mu- 10. Seidah N, Chretien M: Proprotein and prohormone convertases:
A family of subtilases generating diverse bioactive peptides. Braintants bind heparin, if native FGF-23 binds to one of the
Res 848:45–62, 1999four FGFRs, the mutant proteins may be capable of
11. Bergeron F, Leduc R, Day R: Subtilase-like pro-protein con-
activating the same receptor. Indeed, native FGF-23 and vertases: From molecular specificity to therapeutic applications.
J Mol Endocrinol 24:1–22, 2000an artificial double-missense mutant (containing both
12. Nakayama K: Furin: A mammalian subtilisin/Kex2p-like endopro-R176Q and R179Q mutations) were capable of inducing
tease involved in processing of a wide variety of precursor proteins.
hypophosphatemia when injected into mice [abstract; Biochem J 327:625–635, 1997
13. Yang X-F, Fournier H, Dion N, et al: Site-directed mutagenesisShimada, Bone 28(Suppl 5):S89, 2001]. Thus, it is a rea-
and transfection methods in the study of prohormone processing.sonable hypothesis that the mutants bind the same recep-
Neuroprotocols 5:157–168, 1994
tor and activate similar cellular mechanisms as the wild- 14. Kingston RE: Introduction of DNA into mammalian cells, in
Current Protocols in Molecular Biology, edited by Ausubel FM,type protein. Activating mutations in human FGFRs1-3
Brent R, Kingston RE, et al, New York, John Wiley & Sons,result in skeletal dysplasias [reviewed in 36, 37] do not
Inc., 1998, p 9.0.1
lead to phosphate wasting. We propose that if activating 15. Constam DB, Robertson EJ: Regulation of bone morphogenic
protein activity by pro domains and proprotein convertases. J Cellmutations in one of the FGFRs was responsible for a
Biol 144:139–149, 1999phosphate wasting phenotype, the mutation would be
16. DuBois CM, Laprise MH, Blanchette F, et al: Processing of
distinct from those previously identified. Therefore, fur- transforming growth factor beta 1 precursor by human furin con-
vertase. J Biol Chem 270:10618–10624, 1995ther understanding of the relationship between the na-
17. Hendy GN, Bennett HP, Gibbs BF, et al: Proparathyroid hormonetive and the FGF-23 mutants and their receptor, with
is preferentially cleaved to parathyroid hormone by the prohor-
the idea that the mutations lead to increased FGF-23 mone convertase furin. A mass spectromic study. J Biol Chem 270:
9517–9525, 1995stability, may provide insight into the mechanisms under-
18. Liu B, Goltzman D, Rabbani SA: Processing of pro-PTHRP bylying ADHR, as well as other heritable and acquired
the prohormone convertase, furin: Effect on biological activity.
disorders of impaired renal phosphate regulation. Am J Physiol 268(5 Pt 1):E832–E838, 1995
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